ASH 2019 | Daratumumab plus VMP for NDMM: ALCYONE follow-up
Maria-Victoria Mateos, MD, PhD, University Hospital of Salamanca, Salamanca, Spain, outlines the 36 months follow-up from the ALCYONE study (NCT02195479). This phase III trial compares the addition of daratumumab to standard of care regimen of bortezomib, melphalan and prednisone (VMP) with VMP alone in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM). Results demonstrate that the addition of daratumumab to VMP prolongs overall survival with a reduction in the risk of death and continues to support the addition of the monoclonal antibody targeting CD38 to frontline treatment regimens in patients with transplant-ineligible NDMM. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
